Exhibit 10.9
AMENDMENT FOUR
To
LIMITED EXCLUSIVE
PATENT LICENSE AGREEMENT
For
DIAGNOSTIC KIOSK
For Food Safety, Water Quality Monitoring, and
Human/Veterinary Clinical Diagnostics
Between
LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
and
BIONOMICS DIAGNOSTICS, INC.,
a wholly-owned subsidiary of LexaGene Holdings, Inc.
LLNL Case No. TL02679.4
Lawrence Livermore National Laboratory
Innovation and Partnerships Office
P.O. Box 808, L-795, Livermore, CA 94551
September 18, 2019
Bionomics Diagnostics, Inc., a wholly-owned subsidiary LexaGene Holdings, Inc. | Diagnostic Kiosk Amendment Four |
AMENDMENT FOUR
September 18, 2019
to
License Agreement - LLNL Case Number TL02679
for Diagnostic Kiosk
between Bionomics Diagnostics, Inc. and Lawrence Livermore National Security, LLC
effective June 22, 2015
This Amendment Four to the License Agreement by and between Lawrence Livermore National Security, LLC (“LLNS”) and Bionomics Diagnostics, Inc. (“LICENSEE”) is effective as of the date of execution of this Amendment by the last signing Party. This Amendment and the associated License Agreement are subject to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No DE-AC52-07NA27344 with the United States Department of Energy (“DOE”) for the operation of the Lawrence Livermore National Laboratory (“LLNL”).
This Amendment Four will modify Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS). All other terms and conditions remain the same.
Therefore, in consideration of the mutual covenants and obligations recited herein, LLNS and LICENSEE hereby amend the License Agreement as follows:
| 1. | Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS), Paragraph B.5 (Performance Obligations) |
Delete Paragraph B.5 in its entirety and replace with the following:
| B.5 | Performance Obligations |
| B.5.1 | LICENSEE will complete proof-of-concept prototype by January 31, 2018. |
| B.5.2 | LICENSEE will achieve First Commercial Sale (“FCS”) in the United States by December 31, 2020. |
| 8.5.3 | LICENSEE will be granted license by the USDA to sell into veterinary diagnostics markets and receive AOAC certification to sell into food safety markets in the United States by December 31, 2020. |
| 8.5.4 | LICENSEE will achieve cumulative sales of more than Ten Million Dollars ($10,000,000) within three (3) years of FCS. |
| 19GM0918 | 1 | TL02679.4
Amendment Four |
Bionomics Diagnostics, Inc., a wholly-owned subsidiary LexaGene Holdings, Inc. | Diagnostic Kiosk Amendment Four |
| 8.5.5 | LICENSEE will achieve FDA clearance to perform human clinical diagnostics in the United States by December 31. 2022. |
| B.5.6 | The sales requirements specified above may, by mutual written consent of LICENSEE and LLNS, be amended and/or extended at the written request of LICENSEE to LLNS. based upon legitimate business reasons specified in reasonable detail in such written request. |
| 8.5.7 | The first progress report will be due on February 28, 2016. |
| B.5.8 | LICENSEE will diligently proceed to commercially develop, file relevant regulatory applications for, and attempt to obtain relevant regulatory commercialization approvals with respect to the manufacturing, marketing, and sale of Licensed Products. |
LLNS and LICENSEE execute this Amendment, in duplicate originals, by their respective officers who are duly authorized on the day and year that is written.
| BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc | | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC LAWRENCE LIVERMORE NATIONAL LABORATORY |
| By: | /s/ Jack Regan | | By: | /s/ Richard Rankin |
| Name: | Jack Regan | | Name: | Richard A. Rankin |
| Title: | Chief Executive Officer | | Title: | Director, Innovation and Partnerships Office |
| Date Signed: | 9/18/2019 | | Date Signed: | 9/18/2019 |
| | | | | | | |
| 19GM0918 | 2 | TL02679.4
Amendment Four |
